At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 37 enrolled
Drug / intervention
NPC-02drug
Likely dose
Zinc acetate (NPC-02)AI-extracted
Key inclusion· 1
- ✓Diagnosis of Wilson's disease
Key exclusion· 2
- ✕Acute hepatitis
- ✕Malignant tumor
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase3, Open-Label, Clinical Trial of Zinc Acetate for Treatment of Wilson's Disease in Japan.
In Brief
A Phase 3 clinical trial evaluating NPC-02 for Wilson's Disease. Completed, enrolled 37 participants.
Detailed Summary
The purpose of this long-term study is to determine whether Zinc Acetate is effective and safe in the treatment of Wilson's disease among Japanese.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsWilson's Disease
Countries--
Collaborators--
Timeline
Phase 3CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartMar 2005
First PostedSep 2005
Primary CompletionApr 2008
Study CompletionJan 2009
TodayJul 2026
First PostedSep 21, 2005
Enrollment StartMar 1, 2005
Primary CompletionApr 1, 2008
Study CompletionJan 1, 2009
TodayJul 2, 2026
Enrollment to primary: 3.1 yearsPosted 20.8 years ago
Interventions
NPC-02drug
zinc acetate